All press releases
-
Evexta Bio Appoints Edith A. Perez as Scientific Advisor
-
Evexta Bio appoints Robert Doebele as CMO consultant
-
Evexta Bio appoints Shawn M. Leland as Chairman of the Board of Directors
-
Evexta Bio Reports Progress towards Clinical Development of Rupitasertib in Advanced Breast Cancer
-
Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer
-
Evexta Bio Announces the Appointment of Paul Gineste, PharmD, as Chief Development Officer
-
Diaccurate Announces the Appointment of Scott Filosi as CEO and Corporate Name Change to Evexta Bio
-
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
-
Diaccurate receives support from Bpifrance to conduct its DIACC2020 Program on the development of new payloads for antibody-drug conjugates (ADCs)
-
Diaccurate appoints Laurence Riot Lamotte as Chief Financial Officer